IBRX
NASDAQImmunityBio Inc.
News · 26 weeks46+700%
2026-04-192026-10-11
Mix1590d
- Other5(33%)
- SEC Filings4(27%)
- Leadership3(20%)
- Insider2(13%)
- Offering1(7%)
Latest news
25 items- PRImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary TumorsPeer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highlights: 71% complete response (CR) rate in patients with BCG-unresponsive NMIBC CIS, with or withou
- SECSEC Form 8-K filed by ImmunityBio Inc.8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRFDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS DiseaseExpanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), including those with carcinoma in situ (CIS), with or without papillary tumors, and those with papillary-only tumors Papillary disease represents approximately 85% of the NMIBC patient population1 This is the first FDA approval to include BCG-unresponsive NMIBC with papillary-only tumors With this FDA approval, access to ANKTIVA plus BCG expands to include all patients with BCG-unresponsive NMIBC ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approv
- PRImmunityBio to Participate in the Piper Sandler Virtual Oncology SymposiumImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that Dr. Patrick Soon-Shiong, its Founder, Executive Chairman and Global Chief Scientific and Medical Officer, will participate virtually in a fireside chat at the Piper Sandler Virtual Oncology Symposium, taking place October 15-16, 2026. Details of the event are provided below: Piper Sandler Virtual Oncology Symposium – Fireside Chat Participant: Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio Moderator: Ted Tenthoff, Managing Director and Senior Research Analyst, Piper Sandler Date: Friday, October 16, 2026 Time: 1:00-1:25 p.m. ET
- INSIDERSEC Form 4 filed by ImmunityBio Inc.4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by ImmunityBio Inc.4 - ImmunityBio, Inc. (0001326110) (Issuer)
- PRThese High-Voltage Stocks Are Suddenly Impossible to IgnoreDENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)— Today’s market is driven by an outstanding mix of listings, including Alpha Modus Holdings (NASDAQ:AMOD), Stablecoin Development (NYSEAMERICAN:SDEV), ImmunityBio (NASDAQ:IBRX), and NeOnc Technologies Holdings (NASDAQ:NTHI). Alpha Modus: Bitcoin-Fueled Balance Sheet Reset Sends Shares into Overdrive Alpha Modus (NASDAQ:AMOD) emerged as today’s most active mover, with shares surging sharply after the company closed a transaction that dramatically changes the balance-sheet story. On September 30, Alpha Modus completed a PIPE transaction in which investors delivered 3,170 bitcoin to a newly formed wholly owned subsidiary in excha
- PRHLS Therapeutics Announces Board of Directors ChangesTORONTO, Oct. 1, 2026 /CNW/ -- HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.Dr. Maxwell will join the Audit Committee, and Mr. DeLong will join the Compensation and Governance Committee."Linda and Mark bring complementary experience as HLS enters its next phase of growth," said John Welborn, Chair of the Board of HLS. "Linda's medical expertise, healthcare entrepren
- PRPDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of DirectorsGross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the "Initial Closing") of the Company’s Private Investment in Public Equity ("PIPE") transaction. The round was led by Nant Capital, LLC ("Nant") with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the "Milestone Closing") as described below. At the Initia
- PRImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice ChairmanDr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive Chairman ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong. The Office of the Executive Chairman will bring together senior leaders to support Dr. Soon-Shiong on strategy, partnerships, and initiatives intended to advance ImmunityBi
- SECSEC Form 10-Q filed by ImmunityBio Inc.10-Q - ImmunityBio, Inc. (0001326110) (Filer)
- SECImmunityBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 MillionQ2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoption among U.S. urologists and strong market access First-half 2026 net product revenue of $94.8 million, up 121% compared with the first-half of 2025 In July 2026, we announced the Emirates Drug Establishment of the United Arab Emirates granted the broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC for CIS and papillary disease and metastatic NSCLC The FDA accepted for review the Company’s supplemental Biologics License Appl
- SECImmunityBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ImmunityBio, Inc. (0001326110) (Filer)
- PRImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung CancerThe UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) authorization is the first worldwide to span the full spectrum of BCG-unresponsive disease: carcinoma in situ (CIS) with or without papillary tumors, and papillary disease alone without CIS. The Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) granted Marketing Authorization for two ANKTIVA presentations, the broadest approval to date for ANKTIVA including papillary disease and CIS in non-muscle invasive bladder cancer and non-small cell lung cancer in patients who failed checkpoint inhibitors and chemotherapy.
- INSIDERDirector Cohen Cheryl sold $1,246,941 worth of shares (131,210 units at $9.50) as part of a pre-agreed trading plan and exercised 55,979 shares at a strike of $2.98, decreasing direct ownership by 37% to 125,386 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Selecky Christobel sold $1,439,066 worth of shares (159,478 units at $9.02) as part of a pre-agreed trading plan and exercised 159,478 shares at a strike of $2.99 (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Selecky Christobel exercised 96,722 shares at a strike of $2.94 and sold $871,216 worth of shares (96,722 units at $9.01) as part of a pre-agreed trading plan (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERDirector Simon Barry J. sold $196,908 worth of shares (25,000 units at $7.88) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 2,802,788 units (SEC Form 4)4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Blaszyk Michael D4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Wendel Bruce4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Maxwell Linda4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Cohen Cheryl4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Clark Wesley4 - ImmunityBio, Inc. (0001326110) (Issuer)
- INSIDERSEC Form 4 filed by Director Selecky Christobel4 - ImmunityBio, Inc. (0001326110) (Issuer)
IBRX FAQ
7 questionsWhat does ImmunityBio Inc. do?
ImmunityBio, Inc., a clinical-stage immunotherapy company, develops cell and immune therapies to treat cancers and infectious diseases. The company develops Anktiva (N-803), an IL-15 superagonist and PD-L1 that activates natural killer and T effector cells in combination with chemo and trodelvy to treat cancers, such as merkel cell carcinoma, advanced pancreatic cancer, and advanced triple negative breast cancer; and an albumin-linked formulation of doxorubicin (Aldoxorubicin) to treat breast cancer, hodgkin lymphoma, SCLC, sarcoma, and glioblastoma. It also develops a memory T-cell cancer...Where does IBRX stock trade?
ImmunityBio Inc. (IBRX) is listed on NASDAQ.What sector and industry is IBRX in?
ImmunityBio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did ImmunityBio Inc. go public?
ImmunityBio Inc. (IBRX) completed its IPO in 2015.What are analysts saying about IBRX?
ImmunityBio Inc. has had 6 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $1300.00 price target on 2026-03-12. Recent price targets range from $400.00 to $1300.00.What companies are similar to IBRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IBRX side-by-side with any of them on Quantisnow.How can I track IBRX on Quantisnow?
Quantisnow aggregates ImmunityBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBRX to receive live email and push alerts on every new disclosure.